AAP
TARA icon

Arax Advisory Partners’s Protara Therapeutics TARA Stock Holding History

Arax Advisory Partners’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.38K Buy
+1,671
New +$7.95K ﹤0.01% 4521
2025
Q4 		– Sell
-48
Closed -$209 – 4516
2025
Q3 		$209 Buy
+48
New +$155 ﹤0.01% 3445

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Arax Advisory Partners's TARA Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Protara Therapeutics (TARA) in Q2 2026: 1,671 shares worth $6.38K. The stake represents ﹤0.01% of the portfolio and ranks #4521 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in TARA as recently as Q3 2025.

Arax Advisory Partners first reported a position in TARA in Q3 2025 and has held it in 2 quarters since. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Arax Advisory Partners held 1,671 shares of Protara Therapeutics worth $6.38K as of Q2 2026.
  • Protara Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Protara Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4521 holding.
  • Arax Advisory Partners first reported a position in Protara Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.